With around 35% of approved drugs targeting 108 members of GPCRs, this protein family is probably one of the most interesting and challenging targets when designing new drugs that modulate the downstream processes regulated by these proteins.
This new session of PharmWebinars intends to show which are the current challenges and state-of-the-art computational approaches in this area. We have invited three excelent speakers to share how the face the design of new drugs against these complex systems and the challenges they encounter. As usual, the webinar will have a Q&A session to ask and share experiences.
June 22th 2021
- 04:00 PM (CET)
- 10:00 AM (EDT
Latham Biopharm Group
Principal Consultant, In Silico Drug Discovery
Head of CADD & Informatics
- Opportunities for computer-aided drug design to impact the design of drugs against elusive GPCR drug targets.
- Assessment of 3D molecular descriptors in the identification of new molecular scaffolds
- Application of Free Energy Calculations to Lead Optimization in G-protein Coupled Receptors